Researchers at Fred Hutchinson Cancer Center have found that a specific subtype of a microbe commonly found in the mouth is able to travel to the gut and grow within colorectal cancer tumors. This microbe is also […]
Scientific research has linked a person’s microbiome to everything from gut and mental health to immunity and predisposition to cancer. This research comes at a time when there is a burgeoning interest in wellness and […]
The government of the Netherlands has allocated €200 million from the country’s National Growth Fund for a public-private consortium that will conduct research into ‘microbiomes’ and economically interesting applications thereof. The funds, which will add […]
Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, with participation of all existing investors, reflects enthusiasm for […]
BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a […]
Researchers from the Wellcome Sanger Institute, the Olivia Newton-John Cancer Research Institute in Australia, and collaborators, have identified specific strains of bacteria that are linked with a positive response to combination immunotherapy in the largest […]
Clinical Microbiomics announced the acquisition of DNASense ApS, an innovative Danish microbiome CRO specialized in long-read DNA and RNA sequencing technologies, and the associated cutting-edge bioinformatics. The acquisition expands Clinical Microbiomics’ expertise and offering for […]
Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34M financing round. This significant financial milestone was achieved with the support of […]
Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of pHyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the […]